

Central Venous Thrombosis of the Brain After SARS-CoV-2 Infection and mRNA Vaccination

Neurologic Disaster is Even Worse After Injection

Theme: Science and Medicine

By Dr. Peter McCullough Global Research, March 20, 2023 Courageous Discourse 18 March 2023

All Global Research articles can be read in 51 languages by activating the **Translate Website** button below the author's name (desktop version)

To receive Global Research's Daily Newsletter (selected articles), click here.

Follow us on <u>Instagram</u> and <u>Twitter</u> and subscribe to our <u>Telegram Channel</u>. Feel free to repost and share widely Global Research articles.

Proponents of COVID-19 mass vaccination acknowledge that similar disastrous outcomes occur with both SARS-CoV-2 infection and the COVID-19 vaccines (myocarditis, blood clots, neurological problems). They position a tradeoff and suggest you should risk it with the vaccine in hopes its lower than that of the infection. Since 94% of Americans have had the COVID-19, its water under the bridge for the infection. Early therapy reduces the invasive systemic manifestations of the illness and markedly reduces hospitalization and death including from complications. With vaccination its a different story, the full force of engineered Spike protein is felt in the body with each shot and per case, the severity of the side effect is far worse than that with COVID-19.

Tu, et al illustrated this principle while analyzing central venous thrombosis which is a blood clot in the major vein of the brain which is a medical emergency requiring, hospitalization, intravenous or subcutaneous blood thinners, serial imaging, observation and in some cases surgery. Tu attempted to divide cases by large denominators to minimize risk; that is invalid in safety research since not all cases can be found particularly fatal ones without an autopsy. The important findings from Tu are in the tables. Central venous thrombosis after vaccination was a catastrophe with more cases, greater need for therapy, more brain surgery, and higher degrees of neurologic impairment at discharge for those who took the mRNA vaccine.

Deen Access. This is an open access article distributed under the terms of the CC-BY License.

JAMA Network Open. 2022;5(3):e222940. doi:10.1001/jamanetworkopen.2022.2940

March 17, 2022 1/12

ß



Original Investigation | Neurology

C'r TAWA NED

March

Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore

Tian Ming Tu, MRCP; Shen Jia Yi, MRCP; Jasmine Shimin Koh, MRCP; Seyed Ehsan Saffari, PhD; Rebecca Hui Min Hoe, MRCP; Geraldine Jiangyan Chen, BSc; Hui Jin Chiew, MRCP; Carol Huilian Tham, MRCP; Christopher Ying Hao Seet, MRCP; Ming Hui Yong, MRCP; Kok Pin Yong, MRCP; Andrew Che-Fai Hui, MRCP; Bingwen Eugene Fan, MRCP; Benjamin Yong-Qiang Tan, MRCP; Amy May Lin Quek, MRCP; Raymond Chee Seong Seet, MRCP; Leonard Leong Litt Yeo, MRCP, PhD; Kevin Tan, MRCP; Umapathi N. Thirugnanam, MRCP

								Latelet							
Sex/age	Comorbidities	Respiratory	Positive COVID-19 tests	Neurologi	ical COV		ecation of (ount, per 10°/L, range 150-450)	D-dimer (<0.5pg/t	(range Normal	tic lands	Abnormal thrombotic to	ants Torr	iment	mRS on dischart
M/31-40 y		symptoms None	Serology only	Seizures	NA	S t S		65	4.38	Protein thrombi	C, Protain S, anti- n II, ACL, LAC, Factor V Leiden,	None		farin	1
M/31-40 y	None	None	PCR	Headache vomiting	i, NA	r s	Right posterior 3 condytar wein, ight sigmoid anus, right proximal UV	05	4.3	ACL		None	frac	e (had ture of poral bone)	0
M/31-40 y	None	Cough, pleuritic chest pain, fever	PCR	Headache	1		eft transverse 1 ind sigmoid ines	87	<0.19	ACL		None	Dab	igatran	0
M/21-30 y	None	None	Serology only	Headache	e NA	1	35, transverse 3 inus, torcula, igmoid sinuses	21.4	Not done	ACL, LA	. 82GP1	None	LMN	en .	1
M/31-40 y	None	None	PCR	Seizure	NA		eft transverse ind sigmoid inuses, left IJV	55	4.56	Prosain ACL, 82	C, antichrombin III, 121	Protain 5.539 (low) homocysteine elevated, LAC present	e hepi	pical ompression, arim or farin	6
M/21-30 y	Smoker	None	Serology anly	Headache	e NA	5	55, right 3 ransverse inus, right ignold sinus, ight UV, viatearal contical veins	38	<0.5	Protein thrombi 82 GP1	C, Protein S, anti- 1 III, ACL, LAC,	None		arin or LMWH orfarin	1
_		val Venous Th	rombosis Fall-	owing Mee	stender Phi	A SARS-C-M	-7 Vaccination								
able 3. Desc	ription of Cereb	ral Venous Th			Days from	Days from		Platel count, 10º/L	, per	in second	Abasent				ali
Vaccine received	cription of Cereb Sex/age, years	Co-morbid	Presen Ities sympto	rting onts	Days from 1st dose of vaccine	Days from 2nd dose o vaccine	of Location of CVT	count, 10 ⁹ /L (range 150-4	, per o No 150) th	ormal trombotic tests	Abnormal thrombotic tests		ID-19 test	Treatment	mit5 disch
Table 3. Desc	ription of Cereb Sex/age,		Presen Ities sympto	rting onts	Days from 1st dose of	Days from 2nd dose	of Location of	count, 10 ⁿ /L (range	, per 6 No 150) th Pr 10				ID-19 test negative	Treatment Surgical decompressi heparin or warfarin	disch 5
Table 3. Desc Vaccine received DNT162b2	cription of Cereb Sex/age, years	Co-morbid	Presen ities sympto on Headar on, Headar	ting ons che	Days from 1st dose of vaccine	Days from 2nd dose o vaccine	of Location of CVT Right transverse.	count, 10"/L (range 150-4 383 283	L per 6 Na 150) th Pr th LA 82	IPA, Protein C, rotein S, anti- trombin III, ACL	thrombotic tests	PCR		Surgical decompression heparin or	disch 5
Table 3. Desc Vaccine received	Sex/age, years F/61-70 y	Co-morbid Hypertensi Hypertensi	Presen titles sympto on Heada mia, Heada mia, Heada mia, weaks rena, weaks tit, sensor ory of Setters	ting ons che che sided ess and y lons,	Days from 1st dose of saccine 10	Days from 2nd dose o vaccine 9	of Location of CVT Right transverse, sigmoid, UV Right transverse ar	count, 107/L (range 150-4 383 250 4 50	L per 6 Nk 150) th Pr th LA 82 pr Pr	trambotic tests IPA, Protein C, rotein S, anti- trombin III, ACL, AC, 82GP1 AC present, ACL, 2GP1, Protein C	thrombotic tests None None Antichrombin III =	PCR :	negative	Surgical decompressi heparin or warfarin Heparin or	disch 5 on,
Vaccine received INT162b2 BNT162b2	steption of Cereb Sex/age, years F/61-70 y M/71-80 y	Co-morbid Hypertensi Hypertensi hyperlipide diabetes Hyperlipide diabetes typerlipide diabetes	Present titles sympto on Heada on, Heada on, Right s weake mila, sensor ony of FE amia Heada stade s	ting ons che che sided ess and y lons,	Days from 1st dose of saccine 10 28 29	Days from 2nd dose vaccine 9	for Location of CVT Right transverse, sigmoid, UV Right transverse at sigmoid sinu SSS, right transverse sinua, right sigmoid sinu right UV, bilaecal	count, 107/L (range 150-4 383 250 4 50 4 300	, per 6 No (\$50) th 141 141 141 141 141 141 141 141 141 14	Irombotic tests IPA, Protein C, rotein S, anti- trombin III, ACL, AC, B2GP1 AC present, ACL, 2GP1, Protein C rotein S rotein C, Protein C	thrombotic tests None None Astichrombin III = (normal range: 80%-120%)	PCR :	negative negative performed and logy	Surgical decompressi heparin or warfarin Heparin or warfarin	disch S an, 3
Table 3. Desc Vaccine received BNT162b2 BNT162b2 BNT162b2	Sex/age, years F/61-70 y M/71-80 y F/51-60 y	Co-morbid Hypertensi Hypertensi hypertepid diabetes Hypertepid diabetes, T family histo unprovoka	Nesen sympto on Reads on, Right sensor (A, Sensor A, Sen	ting erss che che che sided est and y loss, e che, laft weakness eniting es and par limb	Days from 1st dose of saccine 10 28 29	Days from 2nd dose vaccine 9 7 8	Location of CVT Right transverse, sigmoid, UV Right transverse a sigmoid sinu SSS, right transverse a sigmoid sinu right Live Right transverse	count, 10 ⁹ /1, (range 150-4 383 250 4 250 4 300 4 333 al	L per 0 Nu 1500 th 1500 th	Ireambotic tests IFA, Protain C, arti- rombin B, arti- trombin III, ACL, MC, 82GP1 AC prosent, ACL 2GP1, Protein C rotain S rotain C, Protein ACL, LAC, 82GP rotain C, Protein anti-thrombin (, ACL, LAC, Protein	thrombotic tests None None Astichrombin III = (normal range: 80%-120%)	PCR I PCR I 55% Not p PCR I serol rega	negative negative performed and logy	Surgical decompressi- heparin or warfarin Haparin or warfarin LMWH or LMWH or	disc Son, 3
Vaccine received BNT162b2 BNT162b2 BNT162b2	San/apa, years f(61-70 y M/71-80 y M/51-60 y	Co-morbid Hypertensi Hypertensi Hypertensi diabetes Hypertensi tamity his unprovela Hypertensi Hypertensi	Illes Presen symptic on Heada mia, Heada mia, Heada mia, Heada sensor on, Seiturn on, Seiturn on, Seiturn sensor on, Seiturn innia, Heada sensor on, Seiturn sensor on, Seiturn set us sensor on, Seiturn set us sensor	reing press che che che che che che che che che che	Days from 1st dose of saccine 30 28 29 22	Days from 2nd dose v vaccine 9 7 8	Location of CVT Right Right Varoverse, signoid, I/V varoverse, signoid sime, varoverse as varoverse as varoverse varovers	count, 10 ⁹ /1, (range 150-4 383 250 4 250 4 300 4 333 al	, per 0 Nu 1500 th 1500 th	IPA Protein C, IPA, Protein C, Poslin S, anti- trombin III, ALL, AC, B2GPI AC, B2GPI Coblin S rotein S rotei	ihrombetic tests None Anthrombin II = 80%-120%) None	PCR I PCR I 55% Not p PCR I PCR I estin PCR I	negative negative performed and logy tive	Surgical decompressi- heparinor warfarin Heparinor warfarin LMWH or warfarin LMWH or warfarin	2 2
Vaccine received BNT162b2 BNT162b2 BNT162b2 BNT162b2 BNT162b2 BNT162b2	San/apa, years f(61.70 y f(51.60 y M/51.60 y M/61.70 y	Co-monthid Higgertensi Higgertensi Higgertensi Higgertensi Higgertensi Higgertensi Higgertensi Higgertensi Higgertensi Higgertensi Dates	Nes Prosen symptic on Heada on, Heada on, Right S weaks shift S shift	eing enes che che che che che, laft weakness mitting es and y loss, e e che, laft weakness mitting es and ses and che, laft ses and ses and se	Dags from 1st dose of sectine 10 28 29 22 22 33	Days from 2nd dose vaccine 9 7 8 1 1	Location of CVT Right Varoverse, signoid, I/V varoverse, signoid sime signoid sime sign	count, 10 ⁹ /1 (range 1383 250 4 333 300 5 212 212 224	L per 6 Nul 1500 th 16 16 16 16 16 16 16 16 16 16	hambolic tests PRA, Presain C. repaintS, and. hamboli H, ACC, 2079, Probain C. 2079, Probain C. 2070, Probain C.	Itheambetic tests None Astelhrombin III - (commitments) (c	PCR I PCR I SSSN Not p PCR I seriol rega PCR I PCR I PCR I rega PCR I PCR I seriol rega PCR I rega	negative negative performed and logy trive negative negative and logy	Surgical decompression heparin or warfarin Heparin or warfarin LMWH or warfarin LMWH or warfarin LMWH or warfarin LMWH or dabigatran SSS shrombactor Heparin or	dBsc S 0 3 2 0 3 2
Pable 3. Desc Vaccine received BNT162b2 BNT162b2 BNT162b2 BNT162b2 BNT162b2 BNT162b2	Serviges, years fr/61-70 y M/71-80 y fr/51-60 y M/61-70 y M/61-70 y M/61-70 y M/61-70 y	Co-morbid Hypertensi Hypertensi hypertipid diabetes Hypertipid diabetes Hypertipid diabetes DVT, scar epileps, encephalit hypertipid	Right Sector	ning eres eres cha cha cha cha viors, e e sond y loss, e e sond y loss, e e sond y loss, e e sond sets and sets	Days from 1st desis of watches 10 28 29 22 22 33 19	Days from 2nd dose v vaccine 9 7 8 1 1 11 NA	d Location of CVT Right signostron signostic s	count, 10 ⁹ /1 (range 1383 250 4 333 300 5 212 212 224	, per 2 Nu 2 Nu	memberkit testis IFR, Proteain C, and IFR, Protein C, and IFR, Protein C, and morbini III, ALC, 2021, Protein C totain S rotein C, Protein and - Horsbin C, Protein (C, SCP) Totain S, ACL, AC, SCP	itheombetic tests None None Astablicombin III - Geormal range BDK-120%) None None Asta-PF4 antibody politike, Anti-Hro III = 73% (normal / Asta-PF4 antibody politike, Anti-Hro III = 73% (normal / Asta-BF4 antibody politike, Anti-Hro III = 73% (normal / Asta-BF4 antibody politike, Anti-Hro III = 73% (normal / Asta-BF4 antibody Sata-120%)	PCR I PCR I PC	negative negative performed and logy trive negative negative and logy	Surgical decompression heparin or warfarin Heparin or warfarin LMWH or warfarin LMWH or warfarin LMWH or warfarin LMWH or warfarin Signa of the warfarin LMWH or warfarin Signa of the warfarin LMWH or warfarin Signa of the warfarin Signa of the warfarin LMWH or warfarin Signa of the warfarin LMWH or warfarin Signa of the warfarin Signa of the signa of the warfarin Signa of the signa of	dbic 5 on, 3 2 2 0 3 3 2

Abbreviations: ACL, anticardiolipin antibodies: BGGPI, B2 glycoprotein 1. CVT, cerebral venous thrombools, DVT, deep vein thrombools. HFIA, hepatin-induced platelet activation; ICH, intracranial hemorrhage; UK, internal jugdar veis; LAC, lupus anticoagulant; LMINH, low molecular weight hepatin; mSC, modified Bankin scale, PCR, polymerase durin maction; PA; platelet factor 4 neuroica antibodes; PC, publicoary embolans; SARS CoV2, Severe Acude Respiratory Synchrone Coronavins 2: SSS, superior sagittal sinus; TA, transient lochenic attack. SI conversion factor: To convert platelet counts to $*10^3 \mu L$, multiply by 1.0.

Tu TM, Yi SJ, Koh JS, Saffari SE, Hoe RHM, Chen GJ, Chiew HJ, Tham CH, Seet CYH, Yong MH, Yong KP, Hui AC, Fan BE, Tan BY, Quek AML, Seet RCS, Yeo LLL, Tan K, Thirugnanam UN. Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore. JAMA Netw Open. 2022 Mar 1;5(3):e222940. doi: 10.1001/jamanetworkopen.2022.2940. PMID: 35297971; PMCID: PMC8931554.

Under no circumstances could someone accept a blood clot in the brain with the vaccine in the hopes of not getting COVID-19. That tradeoff is untenable and yet another reason why vaccine promoters have lost trust from a discerning public.

If you find "Courageous Discourse" enjoyable and useful to your endeavors, please subscribe as a paying or founder member to support our efforts in helping you engage in these discussions with family, friends, and your extended circles.

*

Note to readers: Please click the share buttons above. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

Source

Tu TM, Yi SJ, Koh JS, Saffari SE, Hoe RHM, Chen GJ, Chiew HJ, Tham CH, Seet CYH, Yong MH, Yong KP, Hui AC, Fan BE, Tan BY, Quek AML, Seet RCS, Yeo LLL, Tan K, Thirugnanam UN. Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore. JAMA Netw Open. 2022 Mar 1;5(3):e222940. doi: 10.1001/jamanetworkopen.2022.2940. PMID: 35297971; PMCID: PMC8931554.

Featured image is from Children's Health Defense

The Worldwide Corona Crisis, Global Coup d'Etat Against Humanity

by Michel Chossudovsky

Michel Chossudovsky reviews in detail how this insidious project "destroys people's lives". He provides a comprehensive analysis of everything you need to know about the "pandemic" — from the medical dimensions to the economic and social repercussions, political underpinnings, and mental and psychological impacts.

"My objective as an author is to inform people worldwide and refute the official narrative which has been used as a justification to destabilize the economic and social fabric of entire countries, followed by the imposition of the "deadly" COVID-19 "vaccine". This crisis affects humanity in its entirety: almost 8 billion people. We stand in solidarity with our fellow human beings and our children worldwide. Truth is a powerful instrument."

Conservative Risk Benefit Analyses Decide Against COVID-19 Vaccination

ISBN: 978-0-9879389-3-0, **Year:** 2022, PDF Ebook, **Pages**: 164, 15 Chapters



vours for FREE! <u>Click here to download</u>.

support the eBook project by making a donation through Global **Worldwide Corona Crisis" Campaign Page.**

The original source of this article is <u>Courageous Discourse</u> Copyright <u>Corrections</u>, 2023

earch Articles on our Facebook page

Become a Member of Global Research

Articles by: Dr. Peter McCullough

Comment

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will

not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: <u>publications@globalresearch.ca</u>

<u>www.globalresearch.ca</u> contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca